Comparative Pharmacology
Head-to-head clinical analysis: GILDESS 1 5 30 versus GILDESS 24 FE.
Head-to-head clinical analysis: GILDESS 1 5 30 versus GILDESS 24 FE.
GILDESS 1.5/30 vs GILDESS 24 FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) that inhibits gonadotropin release, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial morphology.
Combination of ethinyl estradiol and drospirenone provides contraceptive effect primarily by suppression of gonadotropins (FSH and LH), inhibition of ovulation, and alterations in cervical mucus and endometrium. Drospirenone has antimineralocorticoid activity and antiandrogenic properties.
One tablet orally once daily at the same time each day.
One tablet orally once daily for 24 days, followed by 4 days of placebo (iron tablets). The active tablets contain 0.8 mg norethindrone acetate and 0.025 mg ethinyl estradiol.
None Documented
None Documented
Ethinylestradiol: terminal half-life 13-17 hours (mean 15 h). Desogestrel active metabolite 3-keto-desogestrel: terminal half-life 23-28 hours (mean 25 h). Clinical: steady-state achieved by cycle day 7-10; missed pill instructions based on half-life.
Ethinyl estradiol: terminal half-life ~13-27 hours (mean ~17 hours); drospirenone: terminal half-life ~30-40 hours (mean ~32 hours). Clinical context: Steady-state achieved within 10 days for both components.
Renal: ~55-60% as ethinylestradiol glucuronide and sulfate conjugates; ~40% as desogestrel metabolites (largely as 3-keto-desogestrel glucuronide). Fecal: ~30-35% of desogestrel metabolites; <5% for ethinylestradiol. Biliary: minor for both.
Renal: ~50-60% as metabolites (ethinyl estradiol glucuronide and sulfate conjugates, drospirenone metabolites); fecal: ~40-50% (drospirenone metabolites); biliary excretion contributes to enterohepatic circulation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive